Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Apr. 11, 2024-- Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.
加利福尼亞州艾爾蒙特--(美國商業資訊)--2024年4月11日--Fulgent Genetics, Inc.（納斯達克股票代碼：FLGT）（“Fulgent” 或 “公司”）是一家擁有完善實驗室服務業務和治療開發業務的科技型公司，今天宣佈，將在2024年5月3日星期五開市前發佈2024年第一季度財務業績。管理層將在美國東部時間當天上午 8:30（太平洋時間上午 5:30）爲投資界舉辦電話會議，討論結果並回答問題。
The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.
可以通過公司網站投資者關係部分的網絡直播觀看電話會議， http://ir.fulgentgenetics.com。音頻重播將在同一地點播放。
About Fulgent
關於 Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent's laboratory services business—which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent's therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
Fulgent是一家以技術爲基礎的公司，擁有完善的實驗室服務業務和治療開發業務。Fulgent的實驗室服務業務——以前被稱爲臨床診斷業務，包括技術實驗室服務和由持牌醫生對實驗室結果的專業解釋。Fulgent的治療開發業務專注於開發用於治療各種癌症的候選藥物，該平台採用新型的納米膠囊和靶向治療平台，該平台旨在改善新藥和現有癌症藥物的治療窗口和藥代動力學特徵。該公司的目標是從基因組診斷業務轉變爲一家完全整合的精準醫療公司。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411030986/en/
Investor Relations Contact:
The Blueshirt Group
Melanie Solomon, melanie@blueshirtgroup.com
投資者關係聯繫人：
Blueshirt 集團
梅蘭妮·所羅門， melanie@blueshirtgroup.com
Source: Fulgent Genetics, Inc.
來源：Fulgent Genetics, Inc.
譯文內容由第三人軟體翻譯。